Cell Division Cycle 7 Related Protein Kinase, Pipeline Review, H2 2019 – Lin Bioscience Inc, NMS Group SpA & Sierra Oncology Inc – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cell Division Cycle 7 Related Protein Kinase – Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Summary

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) – Cell division cycle 7-related protein kinase is an enzyme encoded by the CDC7 gene. It phosphorylate substrates that regulate the G1/S phase transition and DNA replication. Overexpression of CDC7 is associated with neoplastic transformation for some tumors.

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Ovarian Cancer, Metastatic Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Esophageal Cancer, Squamous Non-Small Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Blood Cancer, Breast Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Leukemia, Lymphoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Non-Small Cell Lung Cancer, Rectal Cancer, Squamous Non-Small Cell Lung Carcinoma, Transitional Cell Cancer (Urothelial Cell Cancer), Triple-Negative Breast Cancer (TNBC) and Uterine Cancer.

The latest report Cell Division Cycle 7 Related Protein Kinase – Pipeline Review, H2 2019, outlays comprehensive information on the Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

• The report provides a snapshot of the global therapeutic landscape for Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)
• The report reviews Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
• The report assesses Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Topics Covered:

• Introduction
• Report Coverage
• Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) – Overview
• Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) – Therapeutics Development
• Products under Development by Stage of Development
• Products under Development by Therapy Area
• Products under Development by Indication
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) – Therapeutics Assessment
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) – Companies Involved in Therapeutics Development
• Eli Lilly and Co
• Lin Bioscience Inc
• Millennium Pharmaceuticals Inc
• NMS Group SpA
• Sierra Oncology Inc
• Takeda Pharmaceutical Co Ltd
• Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) – Drug Profiles
• LBS-007 – Drug Profile
• LY-3143921 – Drug Profile
• MSK-777 – Drug Profile
• simurosertib – Drug Profile
• Small Molecule to Inhibit CDC7 for Oncology – Drug Profile
• Small Molecules to Inhibit CDC-7 for Pancreatic Cancer – Drug Profile
• Small Molecules to Inhibit CDC7 for Oncology – Drug Profile
• SRA-141 – Drug Profile
• Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) – Dormant Products
• Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) – Discontinued Products
• Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) – Product Development Milestones
• Featured News & Press Releases

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/1c5mdi

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900